SCS adds to iPS portfolio
Wednesday, 08 October, 2008
Stem Cell Sciences [ASX: STC] has licensed technology developed at Cambridge University used to reprogram adult cells into stem cells.
The agreement relates specifically to patents for technology used to generate induced pluripotent stem (iPS) cells from mammalian cells.
The technology was developed by Professor Austin Smith. Smith, director of the Wellcome Trust Centre for Stem Cell Research.
Smith also serves as chairman of SCS's Scientific Advisory Board.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
